Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Recent Selloff Is A 'Buying Opportunity' For This NASH Stock, Says Analyst
06:05pm, Friday, 16'th Sep 2022 Benzinga
Yesterday, Altimmune Inc (NASDAQ: ALT) announced results from a Phase 1b trial evaluating pemvidutide (ALT-801), a novel glucagonlike peptide-1 (GLP-1) and glucagon dual receptor agonist in non-al
What 4 Analyst Ratings Have To Say About Altimmune
05:07pm, Friday, 16'th Sep 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Altimmune (NASDAQ:ALT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan
Expert Ratings for Altimmune
02:13pm, Friday, 16'th Sep 2022 Benzinga
Analysts have provided the following ratings for Altimmune (NASDAQ:ALT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
0
0
0
Last 3
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
05:28pm, Thursday, 15'th Sep 2022 Zacks Investment Research
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
04:12pm, Thursday, 15'th Sep 2022
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket
11:55am, Thursday, 15'th Sep 2022 Benzinga
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A.
Sonnet BioTherapeutics Holdi
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
09:21am, Thursday, 15'th Sep 2022 Benzinga
Gainers
AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.
Avenue Therapeutics,
Altimmune: Overreaction On NASH Data Creates Buying Opportunity
07:36am, Thursday, 15'th Sep 2022
Altimmune stock was trading lower after the release of positive results, achieving both primary and secondary endpoints of phase 1b study with pemvidutide in NASH/obese patients provides a buying oppo
Dow, S&P 500 Turn Lower; Altimmune Shares Slide
06:49pm, Wednesday, 14'th Sep 2022 Benzinga
U.S. stocks pared gains toward the end of trading, with the Dow Jones dropping around 80 points on Wednesday.
The Dow traded down 0.26% to 31,023.34 while the NASDAQ rose 0.23% to 11,660.57. The S&P
Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday's Mid-Day Session
04:28pm, Wednesday, 14'th Sep 2022 Benzinga
Gainers
Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday.
SciSparc Ltd. (NASDAQ: SPRC) gained 68% to $1.3101 after the company announced it entered into an agreeme
Nasdaq Surges 100 Points; Crude Oil Rises 2%
04:04pm, Wednesday, 14'th Sep 2022 Benzinga
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Wednesday.
The Dow traded up 0.52% to 31,266.37 while the NASDAQ rose 0.89% to 11,736.86. The S
Nucor, Altimmune And Some Other Big Stocks Moving Lower On Wednesday
03:04pm, Wednesday, 14'th Sep 2022 Benzinga
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Wednesday. Here are some big stocks recording losses in today’s session.
Vintage Wine Estates, Inc. (NASDAQ: VWE) fell 40
US Stocks Open Higher, Producer Prices Decline for 2nd Month
02:12pm, Wednesday, 14'th Sep 2022 Benzinga
U.S. stocks traded higher this morning, following the release of PPI data for August.
Following the market opening Wednesday, The Dow traded up 0.22% to 31,173.35 while the NASDAQ rose 0.35% to 11,673
Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data
10:30am, Wednesday, 14'th Sep 2022
Source: Shutterstock Altimune (NASDAQ: ALT ) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning. That clinical trial concerns the use
Altimmune's stock falls 44% after sharing data from trial for liver disease treatment
09:06am, Wednesday, 14'th Sep 2022
Shares of Altimmune Inc. ALT, -0.39% tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcohol
